Monoclonal antibody imaging of recurrent and metastatic prostate cancer.
In summary, this agent is safe for administration and more accurate than any currently available imaging modality for the detection of extraprostatic metastases. This agent is still under investigation and some day may aid urologists in the evaluation of prostate cancer by improving preoperative staging and demonstration of advanced disease and postoperative localization of recurrent disease. Improved staging and localization will reduce unnecessary tests and treatment that will lead to reduced morbidity, better management, earlier detection, and intervention in advanced disease and improved cost-effectiveness.
Burgers
J K
JK
Urology Surgeons Inc, Riverside Hospital, Columbus, OH 43214-3901, USA.
Hinkle
G H
GH
Haseman
M K
MK
D000368:Aged; D000911:Antibodies, Monoclonal; D006801:Humans; D018796:Immunoconjugates; D007205:Indium Radioisotopes; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000473:pathology*; D009364:Neoplasm Recurrence, Local; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon
D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D007205:Indium Radioisotopes